119 related articles for article (PubMed ID: 18753120)
1. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.
Macallan DC; Baldwin C; Mandalia S; Pandol-Kaljevic V; Higgins N; Grundy A; Moyle GJ
HIV Clin Trials; 2008; 9(4):254-68. PubMed ID: 18753120
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
Glesby MJ; Albu J; Chiu YL; Ham K; Engelson E; He Q; Muthukrishnan V; Ginsberg HN; Donovan D; Ernst J; Lesser M; Kotler DP
PLoS One; 2013; 8(4):e61160. PubMed ID: 23593417
[TBL] [Abstract][Full Text] [Related]
3. Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Leung V; Chiu YL; Kotler DP; Albu J; Zhu YS; Ham K; Engelson ES; Hammad H; Christos P; Donovan DS; Ginsberg HN; Glesby MJ
HIV Clin Trials; 2016 Mar; 17(2):55-62. PubMed ID: 27077672
[TBL] [Abstract][Full Text] [Related]
4. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
Carr A; Workman C; Carey D; Rogers G; Martin A; Baker D; Wand H; Law M; Samaras K; Emery S; Cooper DA;
Lancet; 2004 Feb; 363(9407):429-38. PubMed ID: 14962523
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
[TBL] [Abstract][Full Text] [Related]
7. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
[TBL] [Abstract][Full Text] [Related]
8. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
9. Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.
Samaras K; Wand H; Law M; Emery S; Cooper DA; Carr A
Curr HIV Res; 2009 Jul; 7(4):454-61. PubMed ID: 19601783
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
Viganò A; Mora S; Manzoni P; Schneider L; Beretta S; Molinaro M; di Natale B; Brambilla P
J Clin Endocrinol Metab; 2005 Jul; 90(7):4075-80. PubMed ID: 15840750
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.
Koutkia P; Canavan B; Breu J; Torriani M; Kissko J; Grinspoon S
JAMA; 2004 Jul; 292(2):210-8. PubMed ID: 15249570
[TBL] [Abstract][Full Text] [Related]
12. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy.
Bickel M; Zangos S; Jacobi V; Lutz T; Knecht G; Goebel F; Staszewski S; Klauke S
HIV Med; 2006 Sep; 7(6):397-403. PubMed ID: 16903985
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
[TBL] [Abstract][Full Text] [Related]
15. A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.
Blümer RM; van der Valk M; Ackermans M; Endert E; Serlie MJ; Reiss P; Sauerwein HP
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1097-104. PubMed ID: 19690066
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
Hadigan C; Yawetz S; Thomas A; Havers F; Sax PE; Grinspoon S
Ann Intern Med; 2004 May; 140(10):786-94. PubMed ID: 15148065
[TBL] [Abstract][Full Text] [Related]
17. Comparison of body composition assessment methods in patients with human immunodeficiency virus-associated wasting receiving growth hormone.
Esposito JG; Thomas SG; Kingdon L; Ezzat S
J Clin Endocrinol Metab; 2006 Aug; 91(8):2952-9. PubMed ID: 16757527
[TBL] [Abstract][Full Text] [Related]
18. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
Andersen O; Haugaard SB; Flyvbjerg A; Andersen UB; Ørskov H; Madsbad S; Nielsen JO; Iversen J
Eur J Clin Invest; 2004 Aug; 34(8):561-8. PubMed ID: 15305891
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic therapy for HIV-associated lipodystrophy.
Benavides S; Nahata MC
Ann Pharmacother; 2004 Mar; 38(3):448-57. PubMed ID: 14755064
[TBL] [Abstract][Full Text] [Related]
20. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
Hansen BR; Haugaard SB; Jensen FK; Jensen JE; Andresen L; Iversen J; Andersen O
HIV Med; 2010 Apr; 11(4):266-75. PubMed ID: 20002779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
